Pharmaceutical industry: waiting for a deadlock
Competition from generic drugs (copies of original drugs) will lead to a reduction in sales of the largest American companies by $67 billion already in 2007-2012, as patent protection for more than 30 drugs will expire. This is almost half of the total revenue of US companies in 2007. Looking at all this, financial analysts do not recommend investing in the securities of pharmaceutical companies. Experts predict the leadership of biotechnologies, in which generics are technologically and legally impossible.
11.07.2008